Aminoglycosides

Classification

Gentamicin, tobramycin, amikacin, streptomycin, neomycin(topical/oral ONLY — too toxic systemic), netilmicin.

Mechanism

Bind 30S essentially IRREVERSIBLY → (1) misreading of genetic code(distorts proofreading→incorrect amino acids→non-functional MISFOLDED proteins, some disrupt bacterial MEMBRANE) + (2) blocks initiation complex/premature termination. Membrane disruption from misreading = WHY bactericidal despite being protein synthesis inhibitor(exception to General Considerations pattern).

Uptake = OXYGEN-DEPENDENT active transport — ONE fact explains: NO anaerobic coverage(no O2-dependent uptake to exploit) + ↓efficacy in abscess/necrotic tissue(low O2) + genuine SYNERGISM with cell-wall-active agents(β-lactams, vancomycin — weakened wall improves uptake independent of O2-transport step) → enterococcal endocarditis synergy(General Considerations).

Pharmacokinetics

Poor oral bioavailability(polar/charged, can’t cross lipid membranes) → parenteral for systemic infection, OR oral/topical specifically FOR poor absorption(neomycin: bowel decontamination pre-surgery, hepatic encephalopathy — reduces gut ammonia flora locally, no systemic toxicity). Concentration-dependent killing + post-antibiotic effect → basis for ONCE-DAILY EXTENDED-INTERVAL dosing(standard practice) — ALSO reduces nephrotoxicity(trough period lets saturable renal tubular uptake partially clear between doses).

Adverse Effects

Nephrotoxicity: accumulates in proximal tubular cells(megalin-mediated endocytosis, SATURABLE — why extended-interval dosing ↓risk) → acute tubular necrosis, generally REVERSIBLE on stopping. Worse +other nephrotoxic agents(loop diuretics, vancomycin, contrast).

Ototoxicity: COCHLEAR + VESTIBULAR components(endolymph accumulation, hair cell damage) — often IRREVERSIBLE(unlike generally-reversible nephrotoxicity — CRITICAL distinction, don’t lump together). ↑risk: +loop diuretics(furosemide’s OWN separate ototoxic potential = ADDITIVE, not coincidental) + pre-existing renal impairment(↓clearance→↑levels). Differential predisposition: streptomycin/gentamicin→more VESTIBULAR; amikacin/kanamycin→more COCHLEAR(secondary detail; main point = both occur, both can be irreversible, monitor either).

Neuromuscular blockade: ↓presynaptic ACh release + some postsynaptic block → curare-like effect. Relevant: +genuine NMB agent during anaesthesia(additive/potentiated) OR pre-existing NM disease(myasthenia gravis — specifically avoided/cautioned, risk of myasthenic crisis). SAME class of interaction as Skeletal Muscle Relaxants topic, applied to an antibiotic.

Clinical Relevance

O2-dependent bacterial uptake = ONE fact explaining THREE seemingly separate rules: no anaerobic coverage, ↓efficacy in abscess/necrotic tissue, genuine β-lactam synergism. Recognizing as ONE mechanism (not 3 memorized facts) = same efficient-holding spirit as amphetamine/tyramine or caffeine/theophylline elsewhere in this subject.

Classification

Gentamicin, tobramycin, amikacin, streptomycin, neomycin (topical/oral only, given systemic toxicity too severe for parenteral use), netilmicin.

Mechanism of Action

Aminoglycosides bind the 30S ribosomal subunit essentially irreversibly, causing two distinct effects that together explain their (unusual, for a protein-synthesis inhibitor) bactericidal action: (1) misreading of the genetic code — the drug distorts the ribosome’s proofreading function, causing incorporation of incorrect amino acids and production of non-functional, misfolded proteins, some of which insert into and disrupt the bacterial cell membrane, and (2) blockade of the initiation complex and premature termination of translation. The membrane-disrupting consequence of misreading is the specific reason aminoglycosides are bactericidal despite being protein synthesis inhibitors — the exception flagged under Antimicrobials — General Considerations’ bactericidal/bacteriostatic pattern.

Uptake into the bacterial cell is an oxygen-dependent, active transport process — this single fact explains two otherwise-separate clinical observations: aminoglycosides have no useful activity against anaerobic organisms (no oxygen-dependent uptake mechanism to exploit) and show markedly reduced efficacy in anaerobic/low-oxygen environments (abscesses, necrotic tissue), and aminoglycosides show genuine synergism with cell-wall-active agents (β-lactams, vancomycin) — a weakened cell wall improves aminoglycoside penetration/uptake independent of the oxygen-dependent transport step, the specific synergy exploited in enterococcal endocarditis (already referenced under Antimicrobials — General Considerations) and other severe Gram-positive infections.

Pharmacokinetics

Poor oral bioavailability (highly polar, charged molecules that cannot cross lipid membranes well) — administered parenterally for systemic infection, or used orally/topically specifically because of this poor absorption when a local, non-absorbed effect is wanted (neomycin for bowel decontamination before surgery, or hepatic encephalopathy management, exploiting negligible systemic absorption to reduce gut ammonia-producing flora locally without systemic toxicity). Concentration-dependent bactericidal killing with a genuine post-antibiotic effect (per Antimicrobials — General Considerations) is the specific pharmacodynamic basis for once-daily, high-dose (extended-interval) dosing regimens, now standard practice — this dosing strategy also happens to reduce nephrotoxicity risk relative to older multiple-daily-dosing regimens, since it allows a trough period of low drug concentration for renal tubular cells (which take up aminoglycoside via a saturable process) to partially clear accumulated drug between doses.

Adverse Effects

Nephrotoxicity: aminoglycosides accumulate in renal proximal tubular cells (taken up via megalin-mediated endocytosis, a saturable process — the mechanistic basis for extended-interval dosing reducing this risk, as above), causing acute tubular necrosis — generally reversible with discontinuation, but a genuine, dose- and duration-related risk requiring regular renal function monitoring during therapy, worse with concurrent use of other nephrotoxic agents (loop diuretics, vancomycin, contrast media).

Ototoxicity: both cochlear (auditory) and vestibular components, from accumulation in inner ear endolymph and damage to hair cells — genuinely often irreversible, unlike the generally-reversible nephrotoxicity, a critical distinction worth stating explicitly rather than lumping both toxicities together as equally reversible. Risk is increased by concurrent loop diuretics (a specific, examined interaction — furosemide’s own, separate ototoxic potential is additive with aminoglycoside ototoxicity, not merely coincidental co-administration risk) and by pre-existing renal impairment (reduced clearance, higher sustained levels). Different aminoglycosides show a differential predisposition toward cochlear versus vestibular toxicity (streptomycin and gentamicin more vestibular; amikacin, kanamycin more cochlear) — a specific, sometimes-examined distinction, though the overall message (both components occur, both can be irreversible, monitor for either) matters more than memorizing which specific agent leans which direction.

Neuromuscular blockade: aminoglycosides can inhibit presynaptic acetylcholine release and have some postsynaptic receptor-blocking activity at the neuromuscular junction, producing a curare-like block — clinically most relevant when combined with a genuine neuromuscular blocking agent during anaesthesia (additive/potentiated block) or in a patient with pre-existing neuromuscular disease (myasthenia gravis, where aminoglycosides are specifically cautioned/avoided given the risk of provoking a myasthenic crisis) — this is the same fundamental class of adverse interaction already covered under Skeletal Muscle Relaxants, worth recognizing as the identical concept applied to an antibiotic rather than a deliberately-administered neuromuscular blocker.

Clinical Relevance

The single fact of oxygen-dependent bacterial uptake explains three seemingly separate clinical rules at once: no anaerobic coverage, reduced efficacy in abscesses/necrotic tissue, and genuine synergism with cell-wall-active agents — recognizing this as one mechanism rather than three memorized facts is the efficient way to hold this topic, in the same spirit as recognizing amphetamine/tyramine or caffeine/theophylline as shared mechanisms elsewhere in this subject.

Oxygen-dependent active uptake into the bacterial cell, linking no-anaerobic-coverage, reduced-efficacy-in-abscess, and β-lactam-synergy into one mechanism.
Extended-interval (once-daily) vs multiple-daily dosing, showing trough-period renal tubular clearance reducing nephrotoxicity.